Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Osaka Saiseikai Nakatsu Hospital |
---|---|
Information provided by: | Osaka Saiseikai Nakatsu Hospital |
ClinicalTrials.gov Identifier: | NCT00575172 |
For the purpose of comparing efficacy of intensive therapy between 1) ultrarapid-acting type insulin (insulin aspart) and 2) conventional rapid-acting type insulin (R), a Multicenter Open Label Randomized Controlled Trial was planned in Japan using the occurrence of cardiovascular events in patients with diabetes, a high risk factor, as an index.
Condition |
---|
Diabetes Mellitus |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | To Investigate Whether the Postprandial Blood Sugar Level as Achieved Using Ultrarapid-Acting Type Insulin Could Prevent Great Vessel Disorder in Japanese Type 2 Diabetic Patients. |
Enrollment: | 346 |
Study Start Date: | March 2003 |
Study Completion Date: | December 2007 |
Groups/Cohorts |
---|
U
Intensified insulin therapy with ultrarapid insulin-analogue (Insulin-Aspart)
|
R
Intensified insulin therapy with human regular insulin
|
A survey shows that the most frequently observed direct cause of death in diabetic patients is cardiovascular disorder. However, investigations and surveys such as DCCT, UKPDS and KUMAMOTO-study, etc. clarified that strict control of blood sugar level prevented development and progress of diabetic microangiopathy, but could not show a significant effect on great vessel disorder. Recently, the DECODA-study, DECODE-study and Honolulu-study have demonstrated that postprandial high blood sugar is involved in great vessel disorder. Therefore, possible prevention of great vessel disorder in diabetic patients is suggested by improving the postprandial blood sugar level as achieved using ultrarapid-acting type insulin, which has become available recently. Even with results in Europe and the US obtained, the life-style and incidence of complications in Japanese people are different, and there are many points that remain uncertain with respect to the direct application of foreign results to Japanese people. Therefore, in Japan also, it is necessary to conduct a large-scale clinical study and to establish high-level evidence using mainly Japanese people through hospitals having many patients.
Ages Eligible for Study: | 20 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Japanese outpatients and inpatients aged 20 years or more but younger than 85 years. Men or women. Patients with type 2 diabetes based on the diagnostic standard of the Japanese Diabetes Society/American Diabetes Association. No specific restriction on the current treatment. Patients having switched treatment are also accepted.
Inclusion Criteria:
Subjects are patients satisfying the following conditions 1) - 3).
Exclusion Criteria:
Japan | |
Osaka Saiseikai Nakatsu Hospital | |
Osaka, Japan, 503-0012 |
Study Chair: | Hideshi Kuzuya, M.D.,Ph.D | Higasiyama Takeda Hospital |
Study Director: | Makoto Otoshi, MD.,Ph.D. | Ohtoshi Clinic |
Principal Investigator: | Haruo Nishimura, MD.,Ph.D. | Osaka Saiseikai Nakatsu Hospital |
Principal Investigator: | Koji Maeda, MD. | Maeda Clinic |
Principal Investigator: | Mitsuyo Shintani, MD.,Ph.D. | Osaka Saiseikai Nakatsu Hospital |
Responsible Party: | NICE-study EBM center ( Osaka Saiseikai Nakatsu Hospital ) |
Study ID Numbers: | UMIN0949, UMIN00000949 |
Study First Received: | December 17, 2007 |
Last Updated: | January 7, 2008 |
ClinicalTrials.gov Identifier: | NCT00575172 |
Health Authority: | Japan: Pharmaceuticals and Medical Devices Agency |
type2 diabetes mellitus cardiovascular disease macrovascular event |
Metabolic Diseases Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases Endocrinopathy |
Metabolic disorder Glucose Metabolism Disorders Insulin Diabetes Complications |